Evaluation of drugs with selective inhibitors targeting the anti-apoptotic protein b-cell lymphoma 2 (bcl-2) with pro-apoptotic and antineoplastic activities in grade iv glioblastoma.

Venetoclax, navitoclax, and obatoclax represented significant advances in apoptosis-targeted therapy, with venetoclax emerging as the most clinically successful agent. However, resistance mechanisms and side effects were significant challenges, necessitating further preclinical and clinical studies to optimize the therapeutic potential of these agents.